Abbott Laboratories (ABT) Short-Term Debt issuances (2009 - 2026)

Abbott Laboratories has disclosed Short-Term Debt issuances across 18 years of filings, most recently posting $31.0 million for Q1 2026.

• Short-Term Debt issuances for Q1 2026 came in at $31.0 million, up 186.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$48.0 million (down 433.33% YoY), and the FY2025 annual result was -$115.0 million, down 15.0% from the prior year.
• Short-Term Debt issuances came in at $31.0 million for Q1 2026 at Abbott Laboratories, up from -$71.0 million in the prior quarter.
• In the past five years, Short-Term Debt issuances ranged from a high of $111.0 million in Q4 2023 to a low of -$127.0 million in Q1 2024.
• The 5-year median for Short-Term Debt issuances is $8.0 million (2022), against an average of -$6.8 million.
• Peak annual rise in Short-Term Debt issuances reached 1010.0% in 2023, while the deepest fall reached 625.0% in 2023.
• Abbott Laboratories' Short-Term Debt issuances stood at $10.0 million in 2022, then surged by 1010.0% to $111.0 million in 2023, then sank by 76.58% to $26.0 million in 2024, then tumbled by 373.08% to -$71.0 million in 2025, then surged by 143.66% to $31.0 million in 2026.
• The last three Short-Term Debt issuances figures came in at $31.0 million (Q1 2026), -$71.0 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.